{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-22-000017","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2022-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.053043+00:00","generated_at":"2026-06-25T08:28:09.374364+00:00","sec_items":["8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vertex Pharmaceuticals acquires Catalyst Biosciences' complement portfolio for $60 million","bullets":["Vertex acquired Catalyst's complement portfolio and related IP, including CB 2782-PEG, for $60 million cash.","The transaction closed on May 19, 2022, and was disclosed in an 8-K filed May 23, 2022.","Vertex will record the $60 million purchase price in GAAP and non-GAAP operating expenses in Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-22-000017","json":"https://secwatch.observer/filing/0000875320-22-000017.json","markdown":"https://secwatch.observer/filing/0000875320-22-000017.md","text":"https://secwatch.observer/filing/0000875320-22-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/0000875320-22-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532022000017/vrtx-20220523.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T08:28:09.374364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}